Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?

Int J Mol Sci. 2024 Mar 15;25(6):3361. doi: 10.3390/ijms25063361.

Abstract

The BMP pathway is one of the major signaling pathways in embryonic development, ontogeny and homeostasis, identified many years ago by pioneers in developmental biology. Evidence of the deregulation of its activity has also emerged in many cancers, with complex and sometimes opposing effects. Recently, its role has been suspected in Diffuse Midline Gliomas (DMG), among which Diffuse Intrinsic Pontine Gliomas (DIPG) are one of the most complex challenges in pediatric oncology. Genomic sequencing has led to understanding part of their molecular etiology, with the identification of histone H3 mutations in a large proportion of patients. The epigenetic remodeling associated with these genetic alterations has also been precisely described, creating a permissive context for oncogenic transcriptional program activation. This review aims to describe the new findings about the involvement of BMP pathway activation in these tumors, placing their appearance in a developmental context. Targeting the oncogenic synergy resulting from this pathway activation in an H3K27M context could offer new therapeutic perspectives based on targeting treatment-resistant cell states.

Keywords: BMP; DIPG; DMG; H3K27M; invasion; pediatric glioma; quiescence.

Publication types

  • Review

MeSH terms

  • Bone Morphogenetic Proteins / metabolism
  • Child
  • Diffuse Intrinsic Pontine Glioma* / genetics
  • Diffuse Intrinsic Pontine Glioma* / metabolism
  • Diffuse Intrinsic Pontine Glioma* / pathology
  • Glioma* / metabolism
  • Histones / metabolism
  • Humans
  • Mutation
  • Signal Transduction

Substances

  • Histones
  • Bone Morphogenetic Proteins

Grants and funding

This research received no external funding.